Felisafe
- Manufacturer
- Feelgood Health | W. Last
- Effective date
- 2010-09-15
- Label type
- OTC ANIMAL DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-01 02:02:37
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - PURPOSE SECTION
4-in-1 protection for immune support
INDICATIONS & USAGE SECTION
Indications: Homeopathic remedy for optimal immune function.
DOSAGE & ADMINISTRATION SECTION
Dosage: Preventative: Sprinkle 1 pinch on the tongue once a day for 3 days and repeat annually. Acute: Sprinkle one pinch on the tongue every two hours. May be administered to kittens younger than 12 weeks – or for newborn kittens and pregnant queens.
GENERAL PRECAUTIONS SECTION
Caution: Consult your vet if symptoms persist or worsen. Keep this and all medicines from the reach of children.
OTC - ACTIVE INGREDIENT SECTION
Ingredients: Each dose contains equal parts of Arsen alb (30C) (HPUS), Phos (30C), Baptisia (30C) (HPUS), Ferrum phos
INACTIVE INGREDIENT SECTION
Sucrose (inactive ingredient).
WARNINGS SECTION
Contains no gluten, artificial flavors, colors or preservatives.
INFORMATION FOR PATIENTS SECTION
All Native Remedies health products are especially
formulated by experts in the field of natural health and are manufactured
according to the highest pharmaceutical standards for maximum safety and
effectiveness. For more information, visit us at
www.petalive.com
Distributed by
Native Remedies, LLC
6531 Park of Commerce Blvd.
Suite 160
Boca Raton, FL 33487
Phone: 1.877.289.1235
International: + 1.561.999.8857
The letters HPUS indicate that the component(s) in this product is (are) officially monographed in the Homeopathic Pharmacopoeia of the United States.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep this and all medicines from the reach of children.
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 63f39a63-5cd1-4016-bd86-2bbb0f6c3139 | Product name | 3 | 20240506 |
| e5a77e9c-c528-733a-173d-914a234c024b | Product name | 5 | 20240506 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68647-105-10 | Felisafe | 20000 mg in 1 BOTTLE, GLASS | GRANULE | 20000 | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ARSENIC TRIOXIDE | ACTIVE INGREDIENT | S7V92P67HO | 1 | |
| BAPTISIA | ACTIVE INGREDIENT | 5K1UO2888Y | 1 | |
| FERRUM PHOSPHORICUM | ACTIVE INGREDIENT | 91GQH8I5F7 | 1 | |
| PHOSPHORUS | ACTIVE INGREDIENT | 27YLU75U4W | 1 | |
| ARSENIC TRIOXIDE | ACTIVE MOIETY | S7V92P67HO | 1 | |
| BAPTISIA | ACTIVE MOIETY | 5K1UO2888Y | 1 | |
| FERRUM PHOSPHORICUM | ACTIVE MOIETY | 91GQH8I5F7 | 1 | |
| PHOSPHORUS | ACTIVE MOIETY | 27YLU75U4W | 1 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 1 |
Products#
Every source-derived product name is available through these pages.
- Felisafe
- Arsen alb, Phos, Baptisia, Ferrum phos
- ARSENIC TRIOXIDE
- PHOSPHORUS
- BAPTISIA
- FERRUM PHOSPHORICUM
- SUCROSE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 68647-105 | 68647-105-10 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| ARSENIC TRIOXIDE | S7V92P67HO | ACTIB |
| PHOSPHORUS | 27YLU75U4W | ACTIB |
| BAPTISIA | 5K1UO2888Y | ACTIB |
| FERRUM PHOSPHORICUM | 91GQH8I5F7 | ACTIB |
| SUCROSE | C151H8M554 | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TROCHE / BUCCAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER / ORAL | 27768 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | PASTILLE / ORAL | 426 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED / ORAL | 145 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, CHEWABLE / ORAL | 7258 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, DELAYED RELEASE / ORAL | 295.33 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION, EXTENDED RELEASE / ORAL | 18790 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SYRUP / ORAL | 46400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | 86 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, EMULSION / INTRAVENOUS | 970 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION / ORAL | 48209 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | 9.4 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | WAFER / ORAL | 155.2 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CONCENTRATE / ORAL | 4800 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, EXTENDED RELEASE / ORAL | 284.54 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 119.12 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | ELIXIR / ORAL | 18000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SUSPENSION, EXTENDED RELEASE / SUBCUTANEOUS | 1 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / SUBLINGUAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / INTRAVENOUS | 1950 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, EXTENDED RELEASE / ORAL | 619 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | 900 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / BUCCAL | 109 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 308 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET, COATED / ORAL | 516.42 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, DELAYED RELEASE / ORAL | 955 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | LIQUID / ORAL | 37500 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SOLUTION / ORAL | 42596 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, SOLUTION / INTRAVENOUS | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 2000 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION, EXTENDED RELEASE / ORAL | 5400 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTION / SUBCUTANEOUS | 47.75 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUPPOSITORY / RECTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | TABLET / ORAL | 4249 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SUSPENSION/ DROPS / ORAL | 3750 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE, COATED PELLETS / ORAL | 59.8 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | DROPS / ORAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | GRANULE, FOR SUSPENSION / ORAL | 31885 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | CAPSULE / ORAL | 3568 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SUSPENSION / ORAL | 40017 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / RECTAL | 35.42 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / TRANSMUCOSAL | 1255 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | SOLUTION / ORAL | 70000 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ARSENIC TRIOXIDE | ARSENIC TRIOXIDE | Nordic Pharma, Inc. | d1e2107c-26c3-40fc-978e-0ba5b84098ac | 2026-10-29 | Boxed warning, Warnings, Adverse reactions | ARSENIC TRIOXIDE |
| Arsenic Trioxide | ARSENIC TRIOXIDE | Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Inc | 8dddfe9e-06bf-4983-9c55-71b19da8fcdc | 2025-11-07 | Boxed warning, Warnings, Adverse reactions | ARSENIC TRIOXIDE |
| Arsenic Trioxide | ARSENIC TRIOXIDE | Fresenius Kabi USA, LLC | a482eccd-8837-47ea-904d-2f2c294d10fa | 2025-08-21 | Boxed warning, Warnings, Adverse reactions | ARSENIC TRIOXIDE |
| ARSENIC TRIOXIDE | ARSENIC TRIOXIDE | Eugia US LLC | 2a999752-f350-4eff-97e7-e7106dfa85b5 | 2025-06-30 | Boxed warning, Warnings, Adverse reactions | ARSENIC TRIOXIDE |
| Arsenic trioxide | ARSENIC TRIOXIDE | Zydus Pharmaceuticals USA Inc. | 3e1d2b63-ccb2-4e97-a009-5983eabf65e4 | 2025-05-14 | Boxed warning, Warnings, Adverse reactions | ARSENIC TRIOXIDE |
| Arsenic trioxide | ARSENIC TRIOXIDE | Zydus Pharmaceuticals USA Inc. | ae5cae02-ca57-4da5-8940-81253fdb8679 | 2025-05-12 | Boxed warning, Warnings, Adverse reactions | ARSENIC TRIOXIDE |
| Arsenic Trioxide | ARSENIC TRIOXIDE | Nexus Pharmaceuticals LLC | 2b2a7ed9-5ed3-42fc-b19b-d50700396233 | 2025-03-03 | Boxed warning, Warnings, Adverse reactions | ARSENIC TRIOXIDE |
| Arsenic trioxide | ARSENIC TRIOXIDE | Zydus Pharmaceuticals USA Inc. | e9d27f88-de82-4379-b143-4b94b3dd8bbe | 2025-02-21 | Boxed warning, Warnings, Adverse reactions | ARSENIC TRIOXIDE |
| Arsenic trioxide | ARSENIC TRIOXIDE | Zydus Pharmaceuticals USA Inc. | e1ad5d87-e65e-402f-86b5-e641fc4e61ab | 2025-02-21 | Boxed warning, Warnings, Adverse reactions | ARSENIC TRIOXIDE |
| Arsenicum Album 200ck | ARSENIC TRIOXIDE | SEVENE USA | c8d6dcbf-a5a9-5231-e053-2a95a90a7354 | 2025-02-11 | Warnings | ARSENIC TRIOXIDE |
| ARSENIC TRIOXIDE | ARSENIC TRIOXIDE | Northstar Rx LLC | 48388282-3768-4309-8982-2766cbc9fd59 | 2024-10-07 | Boxed warning, Warnings, Adverse reactions | ARSENIC TRIOXIDE |
| Arsenic Trioxide | ARSENIC TRIOXIDE | Gland Pharma Limited | 2cb52683-1e74-4831-a771-55a78536cfe5 | 2024-09-12 | Boxed warning, Warnings, Adverse reactions | ARSENIC TRIOXIDE |
| ARSENIC TRIOXIDE | ARSENIC TRIOXIDE | Novadoz Pharmaceuticals LLC | 8849c8f9-ee41-4ccd-8a62-67b04e80a276 | 2024-02-06 | Boxed warning, Warnings, Adverse reactions | ARSENIC TRIOXIDE |
| Arsenicum Album 30c | ARSENIC TRIOXIDE | SEVENE USA | 97e7b573-bdc0-4b04-bf24-a24a037cdd19 | 2024-01-23 | Warnings | ARSENIC TRIOXIDE |
| Arsenicum album | ARSENIC TRIOXIDE | Boiron | 84239859-3fc6-24da-e053-2a91aa0a3420 | 2023-12-21 | ARSENIC TRIOXIDE | |
| Arsenicum album | ARSENIC TRIOXIDE | Boiron | 84effad6-a09f-7420-e053-2a91aa0aa55e | 2023-12-21 | ARSENIC TRIOXIDE | |
| Arsenicum album | ARSENIC TRIOXIDE | Boiron | 8423631c-cc03-91a1-e053-2991aa0ac389 | 2023-12-21 | ARSENIC TRIOXIDE | |
| Arsenicum album | ARSENIC TRIOXIDE | Boiron | af651430-79fe-11e6-8a76-424c58303031 | 2023-12-21 | ARSENIC TRIOXIDE | |
| Arsenicum album | ARSENIC TRIOXIDE | Boiron | 84235a97-161a-175f-e053-2991aa0a16cd | 2023-12-21 | ARSENIC TRIOXIDE | |
| ARSENIC TRIOXIDE | ARSENIC TRIOXIDE | Sintetica US LLC | d921f52f-2f38-4300-ae40-31f00b3a500a | 2023-11-15 | Boxed warning, Warnings, Adverse reactions | ARSENIC TRIOXIDE |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
